



The transaction is effective immediately upon the execution of the collaboration and license agreement.

INCMGA0012 is an investigational monoclonal antibody that inhibits PD-1. It is currently being evaluated as monotherapy in registration-directed trials for patients with MSI-high endometrial cancer, Merkel cell carcinoma and anal cancer.

In 2017, Incyte entered into an exclusive global collaboration and license agreement with MacroGenics, Inc. for global rights to INCMGA0012.